7.99

2.44% -0.20

Xeris Biopharma Holdings Inc (XERS)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$8.19

Offen:

$8.19

24-Stunden-Volumen:

2.18M

Relative Volume:

0.92

Marktkapitalisierung:

$1.29B

Einnahmen:

$181.41M

Nettoeinkommen (Verlust:

$-59.56M

KGV:

-19.02

EPS:

-0.42

Netto-Cashflow:

$-38.83M

1W Leistung:

-2.56%

1M Leistung:

+2.30%

6M Leistung:

+102.28%

1J Leistung:

+187.41%

1-Tages-Spanne:

$7.87

$8.21

1-Wochen-Bereich:

$7.87

$8.46

52-Wochen-Spanne:

$2.7763

$8.505

Xeris Biopharma Holdings Inc Stock (XERS) Company Profile

Firmenname

Xeris Biopharma Holdings Inc

Sektor

Healthcare (1140)

Branche

Biotechnology (637)

Telefon

844-445-5704

Adresse

1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL

Mitarbeiter

394

Twitter

@XerisPharma

Nächster Verdiensttermin

2024-12-08

Neueste SEC-Einreichungen

XERS's Discussions on Twitter

Vergleichen Sie XERS mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
XERS Xeris Biopharma Holdings Inc	7.99	1.32B	181.41M	-59.56M	-38.83M	-0.42
VRTX Vertex Pharmaceuticals Inc	407.79	106.37B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	460.46	59.90B	2.46B	-319.09M	-52.09M	-2.4669
REGN Regeneron Pharmaceuticals Inc	564.63	60.40B	14.21B	4.46B	3.56B	39.69
ARGX Argen X Se Adr	796.92	49.56B	3.06B	1.28B	447.35M	19.67
ONC Beone Medicines Ltd Adr	320.10	36.88B	4.56B	-176.77M	225.30M	-1.7177

Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-08-12	Fortgesetzt	H.C. Wainwright	Buy
2024-11-11	Herabstufung	Piper Sandler	Overweight → Neutral
2024-03-28	Eingeleitet	Oppenheimer	Outperform
2023-08-28	Eingeleitet	Craig Hallum	Buy
2022-10-21	Eingeleitet	Jefferies	Buy
2022-04-28	Eingeleitet	Craig Hallum	Buy
2021-11-17	Eingeleitet	SVB Leerink	Outperform
2021-10-29	Eingeleitet	H.C. Wainwright	Buy
2021-04-07	Fortgesetzt	RBC Capital Mkts	Outperform
2020-02-18	Eingeleitet	Piper Sandler	Overweight
2018-07-16	Eingeleitet	Jefferies	Buy
2018-07-16	Eingeleitet	Leerink Partners	Outperform
2018-07-16	Eingeleitet	RBC Capital Mkts	Outperform

Alle ansehen

Xeris Biopharma Holdings Inc Aktie (XERS) Neueste Nachrichten

02:06 AM

Risk vs reward if holding onto Xeris Biopharma Holdings Inc.2025 Top Decliners & Reliable Entry Point Alerts - newser.com

02:06 AM

Oct 12, 2025

Why Xeris Biopharma Holdings Inc. (2B30) stock could be top winnerQuarterly Trade Report & Low Volatility Stock Recommendations - newser.com

Oct 12, 2025

Oct 10, 2025

When is the best time to exit Xeris Biopharma Holdings Inc.Market Growth Report & Fast Gain Stock Tips - newser.com

Oct 10, 2025

Can Xeris Biopharma Holdings Inc. recover in the next quarter2025 Valuation Update & Reliable Momentum Entry Alerts - newser.com

Oct 10, 2025

Volume spikes in Xeris Biopharma Holdings Inc. stock – what they meanJuly 2025 Macro Moves & Capital Efficiency Focused Ideas - newser.com

Oct 10, 2025

Xeris Biopharma Holdings Inc. stock prediction for this weekJuly 2025 Closing Moves & High Yield Stock Recommendations - newser.com

Oct 10, 2025

What is the fair value estimate for Xeris Biopharma Holdings Inc. (2B30) stock in 2025Weekly Market Summary & Free Safe Entry Trade Signal Reports - newser.com

Oct 10, 2025

Analyzing net buyer seller activity in Xeris Biopharma Holdings Inc.IPO Watch & Reliable Intraday Trade Plans - newser.com

Oct 10, 2025

Oct 09, 2025

Is it time to cut losses on Xeris Biopharma Holdings Inc.2025 Key Highlights & Community Verified Trade Alerts - newser.com

Oct 09, 2025

Measuring Xeris Biopharma Holdings Inc.’s beta against major indicesTrade Risk Summary & Free Growth Oriented Trading Recommendations - newser.com

Oct 09, 2025

How buyback programs support Xeris Biopharma Holdings Inc. (2B30) stock2025 AllTime Highs & Low Risk Growth Stock Ideas - newser.com

Oct 09, 2025

Oct 08, 2025

Weiss Ratings Reiterates Sell (D-) Rating for Xeris Biopharma (NASDAQ:XERS) - MarketBeat

Oct 08, 2025

Xeris Biopharma (NASDAQ:XERS) Stock Price Down 4%Here's What Happened - MarketBeat

Oct 08, 2025

Oct 07, 2025

Xeris Biopharma Holdings (XERS): Exploring Valuation as Analysts Grow Bullish on Breakeven Prospects and Earnings Progress - simplywall.st

Oct 07, 2025

Oct 06, 2025

Xeris Biopharma Reaches New 52-Week High of $8.51, Up 253% - Markets Mojo

Oct 06, 2025

News impact scoring models applied to Xeris Biopharma Holdings Inc.Portfolio Value Summary & Growth Focused Stock Pick Reports - newser.com

Oct 06, 2025

Xeris Biopharma Holdings Inc.’s volatility index tracking explainedMarket Risk Analysis & Low Risk Investment Opportunities - newser.com

Oct 06, 2025

Will Xeris Biopharma Holdings Inc. outperform the marketJuly 2025 Big Picture & AI Enhanced Trading Alerts - newser.com

Oct 06, 2025

Will Xeris Biopharma Holdings Inc. stock deliver shareholder valueJuly 2025 Market Mood & Low Drawdown Momentum Ideas - newser.com

Oct 06, 2025

Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635c4 - MarketScreener

Oct 06, 2025

XERS Back In The Spotlight As Recorlev Surges, Gvoke Steadies, And Keveyis Holds Strong - RTTNews

Oct 06, 2025

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Oct 06, 2025

Oct 05, 2025

Xeris Biopharma's Path Toward Profitability Might Change The Case For Investing In XERS - simplywall.st

Oct 05, 2025

Oct 03, 2025

Xeris Biopharma (XERS) is a Great Momentum Stock: Should You Buy? - sharewise.com

Oct 03, 2025

Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Oct 03, 2025

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS): Are Analysts Optimistic? - Yahoo Finance

Oct 03, 2025